{"name":"Anemia Working Group Romania","slug":"anemia-working-group-romania","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Heparin administration","genericName":"Heparin administration","slug":"heparin-administration","indication":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prophylaxis","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Tinzaparin administration","genericName":"Tinzaparin administration","slug":"tinzaparin-administration","indication":"Other","status":"marketed"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"continuation (darbepoetinum)","genericName":"continuation (darbepoetinum)","slug":"continuation-darbepoetinum","indication":"Anemia associated with chronic kidney disease","status":"marketed"}]}],"pipeline":[{"name":"Heparin administration","genericName":"Heparin administration","slug":"heparin-administration","phase":"marketed","mechanism":"Heparin is an anticoagulant that inhibits blood clotting by enhancing the activity of antithrombin III, which inactivates thrombin and other clotting factors.","indications":["Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prophylaxis","Acute coronary syndrome","Atrial fibrillation with thromboembolism risk","Thromboprophylaxis in surgical and medical patients"],"catalyst":""},{"name":"Tinzaparin administration","genericName":"Tinzaparin administration","slug":"tinzaparin-administration","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"continuation (darbepoetinum)","genericName":"continuation (darbepoetinum)","slug":"continuation-darbepoetinum","phase":"marketed","mechanism":"Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.","indications":["Anemia associated with chronic kidney disease","Anemia in patients with non-myeloid malignancies receiving chemotherapy"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}